Business
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline use in heavily pretreated R/R AML HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the publication of an abstract at the European Hematology Association (EHA) 2026 Congress highlighting the cardiac sa
About this update from Moleculin Biotech, Inc.
[{"type":"image","alt":"Moleculin Biotech, Inc.","displaySize":"","headline":null,"caption":"Moleculin Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113}},"lazy":false},{"type":"text","content":"Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction","length":141,"tagName":"p"},{"type":"text","content":"Data demonstrates Annamycin addresses the principal barrier to anthracycline use in heavily pretreated R/R AML","length":110,"tagName":"p"},{"type":"text","content":"HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the publication of an abstract at the European Hematology Association (EHA) 2026 Congress highlighting the cardiac safety profile of Annamycin (or as known in scientific journals “L-Annamycin”), the Company’s next-generation anthracycline currently in late-stage development for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).","length":479,"tagName":"p"},{"type":"text","content":"The abstract titled, “Cardiac Safety of L-Annamycin Across High Cumulative Anthracycline Exposure: Implications for Relapsed/Refractory AML,” will highlight pooled cardiac safety findings from five completed clinical trials evaluating Annamycin in heavily pretreated patients, including those with substantial prior anthracycline exposure. Importantly, the analysis demonstrated no clinically significant treatment-related cardiotoxicity across cumulative anthracycline-equivalent doses that exceeded conventional lifetime exposure limits associated with traditional anthracyclines.","length":582,"tagName":"p"},{"type":"text","content":"Anthracyclines remain among the most effective agents in AML treatment, but the...